ATE439845T1 - Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen - Google Patents
Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauenInfo
- Publication number
- ATE439845T1 ATE439845T1 AT01989306T AT01989306T ATE439845T1 AT E439845 T1 ATE439845 T1 AT E439845T1 AT 01989306 T AT01989306 T AT 01989306T AT 01989306 T AT01989306 T AT 01989306T AT E439845 T1 ATE439845 T1 AT E439845T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen
- women
- replacement therapy
- androgen
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25814200P | 2000-12-22 | 2000-12-22 | |
PCT/US2001/051045 WO2002058706A2 (en) | 2000-12-22 | 2001-12-21 | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE439845T1 true ATE439845T1 (de) | 2009-09-15 |
Family
ID=22979245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01989306T ATE439845T1 (de) | 2000-12-22 | 2001-12-21 | Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen |
Country Status (11)
Country | Link |
---|---|
US (3) | US20020151530A1 (de) |
EP (2) | EP1343509B1 (de) |
JP (2) | JP4768955B2 (de) |
KR (1) | KR100849919B1 (de) |
AT (1) | ATE439845T1 (de) |
AU (1) | AU2002243411B2 (de) |
CA (1) | CA2431645C (de) |
DE (1) | DE60139634D1 (de) |
ES (1) | ES2389639T3 (de) |
MX (1) | MXPA03005742A (de) |
WO (1) | WO2002058706A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2441252A1 (en) * | 2001-03-16 | 2002-10-10 | Wyeth | Estrogen replacement therapy |
WO2003041719A1 (en) * | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Method of contraception in mammalian females and pharmaceutical kit for use in such method |
US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
US8980930B2 (en) * | 2004-06-25 | 2015-03-17 | The Johns Hopkins University | Angiogenesis inhibitors |
US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
WO2006084082A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
CA2635575A1 (en) * | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US20100155594A1 (en) * | 2008-12-23 | 2010-06-24 | Goldman Mildred M | Mass spectrometry assay for estrogenic compounds |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
MX365818B (es) | 2011-11-23 | 2019-05-30 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5688765A (en) * | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
JPH10279483A (ja) * | 1997-02-04 | 1998-10-20 | Kaken Pharmaceut Co Ltd | 骨密度増加剤 |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
EP1187618A1 (de) * | 1999-06-04 | 2002-03-20 | The General Hospital Corporation | PHARMAZEUTISCHE FORMüLIERUNGEN ZUR BEHANDLUNG VON FRAUEN IN DER POSTMENOPAUSE UND PERIMENOPAUSE UND DEREN ANWENDUNG |
CA2376797C (en) * | 1999-06-11 | 2011-03-22 | Watson Pharmaceuticals, Inc. | Administration of non oral androgenic steroids to women |
-
2001
- 2001-12-20 US US10/029,424 patent/US20020151530A1/en not_active Abandoned
- 2001-12-21 AU AU2002243411A patent/AU2002243411B2/en not_active Ceased
- 2001-12-21 ES ES09168004T patent/ES2389639T3/es not_active Expired - Lifetime
- 2001-12-21 CA CA2431645A patent/CA2431645C/en not_active Expired - Fee Related
- 2001-12-21 EP EP01989306A patent/EP1343509B1/de not_active Expired - Lifetime
- 2001-12-21 WO PCT/US2001/051045 patent/WO2002058706A2/en active IP Right Grant
- 2001-12-21 EP EP09168004A patent/EP2116250B1/de not_active Expired - Lifetime
- 2001-12-21 MX MXPA03005742A patent/MXPA03005742A/es active IP Right Grant
- 2001-12-21 JP JP2002559040A patent/JP4768955B2/ja not_active Expired - Fee Related
- 2001-12-21 DE DE60139634T patent/DE60139634D1/de not_active Expired - Lifetime
- 2001-12-21 KR KR1020037008339A patent/KR100849919B1/ko not_active IP Right Cessation
- 2001-12-21 AT AT01989306T patent/ATE439845T1/de not_active IP Right Cessation
-
2003
- 2003-04-29 US US10/424,243 patent/US20030195177A1/en not_active Abandoned
-
2006
- 2006-03-07 US US11/369,458 patent/US20060154907A1/en not_active Abandoned
-
2009
- 2009-11-26 JP JP2009268655A patent/JP2010077149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2116250A1 (de) | 2009-11-11 |
CA2431645A1 (en) | 2002-08-01 |
JP4768955B2 (ja) | 2011-09-07 |
WO2002058706A2 (en) | 2002-08-01 |
DE60139634D1 (de) | 2009-10-01 |
ES2389639T3 (es) | 2012-10-30 |
EP1343509A2 (de) | 2003-09-17 |
WO2002058706A3 (en) | 2003-03-13 |
US20020151530A1 (en) | 2002-10-17 |
MXPA03005742A (es) | 2003-09-05 |
AU2002243411B2 (en) | 2007-02-08 |
EP2116250B1 (de) | 2012-06-20 |
US20060154907A1 (en) | 2006-07-13 |
KR100849919B1 (ko) | 2008-08-04 |
JP2004520375A (ja) | 2004-07-08 |
JP2010077149A (ja) | 2010-04-08 |
CA2431645C (en) | 2010-04-27 |
EP1343509B1 (de) | 2009-08-19 |
KR20030068187A (ko) | 2003-08-19 |
US20030195177A1 (en) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE439845T1 (de) | Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen | |
DE69432990D1 (de) | PROGESTAGEN-FREIE FORMULIERUNGEN VON GnRH UND ESTROGEN ZUR BEHANDLUNG VON BENIGNEN GYNÄKOLOGISCHEN STÖRUNGEN | |
DE69731302D1 (de) | Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden | |
DE60141587D1 (de) | Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern | |
DE59510714D1 (de) | Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann | |
DE60324431D1 (de) | Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs | |
DE60228583D1 (de) | Verfahren und materialien für die behandlung des testosteron-mangels bei männern | |
ATE212841T1 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
DE60330888D1 (de) | Verwendung von drospirenon zur behandlung von hypertension | |
HUP9901505A2 (hu) | Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE270554T1 (de) | Kombination der progesteron und mifepristone für krebs-therapie | |
CH1272195H1 (de) | ||
DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen | |
DE60334830D1 (de) | Furin-hemmer zur behandlung von fibrose und narbenbildung | |
DE59904042D1 (de) | Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor | |
ATE506986T1 (de) | Substanzen und mittel zur positiven beeinflussung von kollagen | |
ATE264101T1 (de) | Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose | |
DE69900774D1 (de) | Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen | |
ATE375160T1 (de) | Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
ATE251460T1 (de) | Verwendung von danazol zur behandlung von hypogonadismus in männern | |
NO20014180D0 (no) | Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser eller oppmerksomhetshunger | |
ATE236640T1 (de) | Budesonid zur behandlung von cholestatischen lebererkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |